Nanjing Immunophage Biomedical Co., Ltd.
PrivateLast Round
Series B
Mar 13, 2023
Total Funding Raised
$89.9M
Company Overview
Nanjing Immunophage Biomedical Co., Ltd. operates in Healthcare & Life Sciences and is based in Nanjing. Its latest recorded funding round was a Series B round in March 2023.
Nanjing Immunophage Biomedical Co., Ltd. is a biotechnology company that researches and develops innovative medicines for the treatment of cancer, autoimmune diseases, and neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanjing Immunophage Biomedical Co., Ltd. Comparables
Compare Nanjing Immunophage Biomedical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kainova Therapeutics | 81% | |
| InnoCare Pharma Limited | 79% | |
| Bristol Myers Squibb | 74% |
For institutional investors. Book with your work email.
Nanjing Immunophage Biomedical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 13, 2023 | ||||
| Series A Extension | Sep 29, 2021 | ||||
| Series A | May 11, 2021 | ||||
| Pre Seed | May 1, 2020 | ||||
| Strategic | Oct 31, 2019 |
For institutional investors. Book with your work email.
Nanjing Immunophage Biomedical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zhongbo Juli | Series B |
| FountainBridge Capital | Series A Extension |
| Daoyuan Capital | Series A Extension |
| Yijing Capital | Series A Extension |
| Ennovation Ventures | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2023
$29M round led by Zhongbo Juli
- Sep 29, 2021
$16M round led by Yijing Capital and M Squared Capital.
For institutional investors. Book with your work email.
Nanjing Immunophage Biomedical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nanjing Immunophage Biomedical Co., Ltd.'s valuation, stock price, and market status.
Is Nanjing Immunophage Biomedical Co., Ltd. a public or private company?
Nanjing Immunophage Biomedical Co., Ltd. is a private company.
What is the current stock price of Nanjing Immunophage Biomedical Co., Ltd.?
Nanjing Immunophage Biomedical Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Nanjing Immunophage Biomedical Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nanjing Immunophage Biomedical Co., Ltd. worth (valuation)?
Valuation information for Nanjing Immunophage Biomedical Co., Ltd. is not publicly available.
Can I buy Nanjing Immunophage Biomedical Co., Ltd. stock?
Nanjing Immunophage Biomedical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nanjing Immunophage Biomedical Co., Ltd.'s last funding round?
Nanjing Immunophage Biomedical Co., Ltd.'s most recent funding round was Series B on March 13, 2023.
Who are the main investors in Nanjing Immunophage Biomedical Co., Ltd.?
Key investors in Nanjing Immunophage Biomedical Co., Ltd. include Zhongbo Juli, Yijing Capital.
Will Nanjing Immunophage Biomedical Co., Ltd. IPO soon?
No public IPO plans have been announced for Nanjing Immunophage Biomedical Co., Ltd..
How can I track Nanjing Immunophage Biomedical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Nanjing Immunophage Biomedical Co., Ltd.'s shares on secondary markets.